Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Curr Opin Gastroenterol. 2013 Mar;29(2):222-7. doi: 10.1097/MOG.0b013e32835d9ff8.
The obesity epidemic over the world has called to attention different ways to manage this development. As bariatric surgery today is the only manner by which rapid and sustained weight control can be achieved, new ways of treating obesity are under investigation. This review focuses on today's knowledge on satiety signaling as a means to combat obesity.
The combined knowledge achieved from obesity surgery with gastric bypass and duodenal switch together with the pharmacological treatment of type 2 diabetes have given us some clues of how to manage obesity. The basis for our understanding is the present research focusing on the gut peptide hormones that are released in response to food intake, and the paucity of satiety signaling seems to prevail in obesity. This means that obese patients experience less activation of higher brain centers in association with a meal and therefore compensate with increased meal size or frequent food intake.
Altered satiety signaling primarily emanating from the gastrointestinal tract seems to lead to the development of obesity and type 2 diabetes. Pharmacological tools that enhance the gut hormone signaling are in focus for the upcoming venues of treatment.
全球肥胖症的流行促使人们关注管理这种趋势的不同方法。由于目前为止减重手术是实现快速且持续的体重控制的唯一方法，因此新的肥胖症治疗方法正在被研究。本综述重点介绍了目前饱腹感信号作为治疗肥胖症的手段的相关知识。
肥胖症手术（胃旁路术和十二指肠转位术）与 2 型糖尿病的药物治疗相结合，结合起来为我们提供了一些管理肥胖症的线索。目前的研究主要集中在响应食物摄入而释放的肠道肽激素，我们的理解基础是，饱腹感信号的缺乏似乎在肥胖症中普遍存在。这意味着肥胖患者在进食时大脑高级中枢的激活程度较低，因此会通过增加每餐的食量或增加进食频率来进行补偿。
主要源自胃肠道的饱腹感信号改变似乎导致了肥胖症和 2 型糖尿病的发生。增强肠道激素信号的药物工具是未来治疗的重点。
